REALY

What REALY does

Hangzhou Realy Tech Co., Ltd. (REALY) is a privately held Chinese in-vitro diagnostic (IVD) medical device manufacturer founded in 2015 and headquartered in Xiaoshan District, Hangzhou, on a 68,000 square meter science park campus. The company develops and manufactures diagnostic products across three complementary technology platforms: chemiluminescence immunoassay (CLIA), colloidal gold rapid testing, and point-of-care testing (POCT), covering approximately 150 immune markers across cardiovascular disease, infectious disease, hepatitis, diabetes, women's health, tumor markers, cardiac markers, drugs of abuse, and other clinical areas. Its core hardware products include the MINI Automatic Chemiluminescence Immunoassay Analyzer and the RL-A2000 POCT quantitative immunoassay analyzer, supported by a broad reagent menu and rapid test cassettes including COVID-19 antigen/antibody tests, Monkeypox detection kits, and multiplex respiratory panels.

REALY operates a B2B go-to-market model selling directly to large and medium-sized hospitals and laboratories, to government and public health departments, and through OEM and OTC/retail channels, with a distribution network spanning 80+ countries across Asia, Europe, the Middle East, Africa, the Americas, and Oceania. The company holds multiple international regulatory certifications—ISO 13485, CE Mark, Australian TGA, Thai FDA, and China NMPA—and markets through international medical exhibitions (Medlab, Medica, AACC), a multilingual website supporting 45+ languages, and OEM partnerships. Manufacturing is integrated on-site with a stated daily production capacity of 100,000 diagnostic doses. The company is founder-led (Chairman and CEO Pengfei Ding), employs 500+ staff including 200+ R&D scientists, and has not raised institutional equity capital since 2018.

Name

REALY

Legal name

Hangzhou Realy Tech Co., Ltd.

Website

https://realytech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Hangzhou Realy Tech (REALY) is a Chinese IVD medical device manufacturer developing chemiluminescence immunoassay analyzers, colloidal gold rapid tests, and POCT platforms covering approximately 150 immune markers, serving hospitals, laboratories, government agencies, and OTC markets across 80+ countries.

Ownership category

akta.pro rank

Product category

In-Vitro Diagnostics (IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical Equipment and Supplies Manufacturing (3391)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Home Diagnostic & Self-Test OTC Kits (HLAIADAO)

Keywords

• In-vitro diagnostics
• Immunoassay analyzers
• Rapid test kits
• Point-of-care testing
• Clinical diagnostics

Headquarters

HQ city

Xiaoshan

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. IVD Products and Test Kits Sales: Sale of in-vitro diagnostic products including rapid tests, immunoassay reagents, and analyzers to healthcare facilities and laboratories worldwide

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

REALY designs, manufactures, and sells in-vitro diagnostic (IVD) products for clinical laboratories, hospitals, government health programs, and OTC channels. Its portfolio spans chemiluminescence immunoassay analyzers and reagents, colloidal gold rapid test kits, point-of-care testing (POCT) devices, and disease-specific rapid tests for infectious diseases, cardiac markers, tumor markers, women's health, drugs of abuse, COVID-19, and Monkeypox. Products are produced at an ISO 13485-certified, NMPA-inspected facility in Hangzhou, China, and distributed through direct sales, OEM partnerships, and an international channel network spanning 80+ countries.

Product overview

Hangzhou Realy Tech Co., Ltd. (REALY) is an In-Vitro Diagnostic (IVD) product manufacturer offering a comprehensive portfolio of rapid test and immunoassay products. The product architecture consists of multiple complementary product lines: (1) COVID-19/SARS-CoV-2 Rapid Test Kits including antigen tests, antibody tests (IgG/IgM), neutralizing antibody tests, and combo tests with Influenza A&B; (2) Chemiluminescence Immunoassay System featuring the MINI Automatic Chemiluminescence Immunoassay Analyzer paired with assay reagents covering TORCH, hormones, tumor markers, cardiac markers, infectious diseases, diabetes, thyroid function, bone metabolism, thrombus, allergy, and DOA panels; (3) Colloidal Gold Rapid Tests for drug abuse (DOA), infectious diseases, women's health, tumor markers, and cardiac markers; (4) POCT (Point of Care Testing) Products including the RL-A2000 quantitative immunoassay analyzer; and (5) Monkeypox Virus detection products. All systems support detection of nearly 150 kinds of immune markers covering cardiovascular diseases, infectious diseases, hepatitis, diabetes, and other fields. The company operates manufacturing facilities in Hangzhou, China, with distribution to over 140 countries.

Differentiator

Problem solved

Functional benefit

Products and services

• COVID-19 / SARS-CoV-2 Rapid Test Kits Rapid diagnostic kits for SARS-CoV-2 covering antigen, antibody (IgG/IgM), neutralizing antibody, and combo respiratory panels, intended for hospitals, labs, public health agencies, and OTC self-testing in approved markets.
• MINI Automatic Chemiluminescence Immunoassay Analyzer Automated benchtop chemiluminescence immunoassay system for quantitative detection of immune markers, paired with the company's CLIA reagent portfolio and sold to clinical laboratories and hospitals.
• Chemiluminescence Immunoassay Assay Reagents Reagent kits for use on REALY's CLIA analyzer covering TORCH (Toxoplasma, Others, Rubella, CMV, Herpes), hormones, tumor markers, cardiac markers (CK-MB, cTnI, NT-proBNP), infectious diseases, diabetes, thyroid function, bone metabolism, thrombus, allergy, and DOA panels. Sold to hospital and reference lab customers.
• Colloidal Gold Rapid Tests Lateral flow rapid test products using colloidal gold immunoassay technology, covering drugs of abuse, infectious diseases, women's health, tumor markers, and cardiac markers, sold to clinical, government, and OTC channels.
• POCT Quantitative Immunoassay Analyzer RL-A2000 Portable point-of-care immunoassay analyzer (RL-A2000) used with quantitative POCT test consumables for rapid on-site diagnostic results at the bedside or in smaller healthcare facilities.
• POCT (Point of Care Testing) Products Broader POCT product line combining POCT analyzers (such as the RL-A2000) with quantitative rapid test consumables for bedside and on-site diagnostics in hospitals, clinics, and field settings.
• Monkeypox Virus (MPV) Tests Human Monkeypox Virus (MPV) detection products, including a Real-Time PCR Assay Kit and an IgG/IgM Antibody Rapid Test Device, sold to public health agencies and clinical laboratories.
• Drugs of Abuse (DOA) Test Products Drug abuse testing products including rapid test devices and drug test readers, sold to clinical laboratories, workplaces, and government agencies for drug screening.

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Dubai World Trade Center / Medlab Middle EastcoreStrategic or Co-development Partner · 6 February 2023Active participation in Medlab Middle East exhibition held at Dubai World Trade Center in February 2023, representing the company's 'going out' strategy for international cooperation and market expansion.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Beijing Hotgen Biotech: Chinese IVD player with strong presence in chemiluminescence, lateral flow, and infectious disease diagnostics. Comparable menu breadth, China-domestic manufacturing, and emerging-market export footprint.
• Hangzhou AllTest Biotech: China-based IVD manufacturer specializing in rapid lateral-flow diagnostic tests (infectious disease, drugs of abuse, fertility, cardiac markers). Directly comparable to REALY in product mix, customer base, and export-driven GTM across emerging markets.
• SD Biosensor: Korea-headquartered IVD company (subsidiary of Standard Diagnostics) with leading position in COVID-19 antigen and rapid diagnostic tests. Comparable product mix, regulatory certifications, and emerging-market distribution.
• Guangzhou Wondfo Biotech: One of China's largest IVD rapid-test exporters with a comparable menu spanning infectious disease, cardiac, fertility, and DOA. Competes head-to-head with REALY on tenders in LATAM, Africa, and Southeast Asia.
• Shenzhen New Industries Biomedical (Snibe): Chinese chemiluminescence immunoassay (CLIA) specialist with a global installed base of MAGLUMI analyzers and broad assay menu. Closest direct competitor to REALY's MINI Automatic CLIA Analyzer and reagent business.
• Getein Biotech: Nanjing-based IVD and POCT manufacturer with overlapping CLIA, colloidal gold, and quantitative immunoassay platforms. Competes in hospital lab and POCT segments across similar geographies.
• Shenzhen YHLO Biotech: Chinese CLIA-focused IVD manufacturer with iFLASH analyzers and a broad reagent menu. Direct competitor to REALY's MINI CLIA Analyzer in mid-tier hospital lab tenders globally.

Broad incumbents

• Autobio Diagnostics: Larger, listed Chinese IVD and clinical lab automation company. Overlaps with REALY's immunoassay reagents and CLIA systems but operates a broader portfolio including microbiology and lab automation.
• Mindray: Largest Chinese medical device / IVD player with comprehensive CLIA, hematology, and ultrasound portfolios. Competes with REALY in reagent/analyzer sales but operates at much larger scale with global service infrastructure.

Emerging players

• ABON Biopharm: China-based IVD manufacturer focused on rapid diagnostic tests (infectious disease, fertility, DOA) with strong emerging-market distribution. Smaller scale than REALY but overlapping product lines and customer base.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/qianqia57006013
• Facebookfacebook.com/Hangzhou-Realy-Tech-Co-Ltd-102373199216825
• LinkedInlinkedin.com/company/82318148
• Instagraminstagram.com/chenqian2023

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about REALY